BMS 262084

Drug Profile

BMS 262084

Latest Information Update: 29 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Antithrombotics; Azetidines; Piperazines; Small molecules
  • Mechanism of Action Factor XIa inhibitors; Tryptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombosis
  • Discontinued Allergic asthma

Most Recent Events

  • 10 Jul 2014 Phase-I clinical trials in Thrombosis in USA (Parenteral)
  • 10 Jul 2014 Phase-I clinical trials in Thrombosis in USA (PO)
  • 31 Dec 2012 Preclinical trials in Thrombosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top